The DOI matches its Crossref record.
New WHO Classification of Endometrial Hyperplasias
Open accessAbstract
Endometrioid endometrial carcinoma, the most common form of endometrial cancer, usually develops out of a typical sequence of endometrial hyperplasias. The underlying cause of these hyperplasias is a relative predominance of estrogen combined with insufficient progesterone levels. Typical causes include corpus luteum insufficiency/anovulatory cycles (premenopause), polycystic ovary syndrome and obesity with metabolic syndrome (aromatase conversion of ovarian androgens in adipose tissue), inappropriate hormone therapy post menopause (insufficient dosage of gestagens) or an estrogen or androgen-producing tumor [ 1 ]. Even in patients with Lynch syndrome (formerly known as HNPCC), tumorigenesis of hereditary endometrioid carcinoma usually follows the usual progression with development of the respective hyperplasias [ 1 ]. Up to now, the correct clinical evaluation of endometrial hyperplasias was made more difficult by the different classification systems still in use: in Germany hyperplasias are sometimes still differentiated according to the classification “glandular-cystic hyperplasia” and “adenomatous hyperplasia grade I to III”. In 1994, the WHO classified endometrial hyperplasias into 4 categories: simple hyperplasia without atypia, complex hyperplasia without atypia, simple atypical hyperplasia, complex atypical hyperplasia [ 1 ], [ 2 ]. While categories 1, 2 and 4 were generally accepted, pathologists continued to debate the existence of group 3-type hyperplasias. Hyperplasias without atypia (categories 1 and 2) are considered benign pathologies which will regress with conservative treatment (oral gestagens, gestagen IUD, elimination of the cause of anovulation/corpus luteum insufficiency) [ 1 ]. A large percentage (up to 60 %) [ 3 ] of atypical endometrial hyperplasias (categories 3 and 4) are found to be coexistent with invasive endometrial carcinoma or develop into invasive endometrial carcinoma within the space of just a few years [ 1 ], [ 2 ], [ 4 ]. Hysterectomy (total hysterectomy, not supracervical hysterectomy!) is therefore the treatment of choice for atypical endometrial hyperplasia [ 4 ] or – in selected patients, i.e. younger patients wanting to have children – high-dose gestagen therapy with appropriate close histological monitoring [ 1 ], [ 4 ]. The WHO classification of 1994 and even more so the parallel use of the older classification system led to confusion among clinicians. The consequence of this was inadequate diagnosis, with hysterectomies performed for hyperplasias without atypia or gestagens administered in HRT dosages for atypical hyperplasia. Pathologists also experienced difficulties with categorization. This was made even more difficult by the development and parallel use of a further classification system: benign hyperplasia and endometrial intraepithelial neoplasia (EIN) [ 2 ]. In its latest classification [ 5 ] published in 2014, the WHO has clarified the matter: it now only differentiates between 2 categories of endometrial hyperplasia: hyperplasia without atypia atypical hyperplasia/endometrioid intraepithelial neoplasia ([ Table 1 ]). Table 1 New WHO classification of endometrial hyperplasias [ 5 ]. New term Synonyms Genetic changes Coexistent invasive endometrial carcinoma Progression to invasive carcinoma Hyperplasia without atypia Benign endometrial hyperplasia; simple non-atypical endometrial hyperplasia; complex non-atypical endometrial hyperplasia; simple endometrial hyperplasia without atypia; complex endometrial hyperplasia without atypia Low level of somatic mutations in scattered glands with morphology on HE staining showing no changes < 1 % RR: 1.01–1.03 Atypical hyperplasia/endometrioid intraepithelial neoplasia Complex atypical endometrial hyperplasia; simple atypical endometrial hyperplasia; endometrial intraepithelial neoplasia (EIN) Many of the genetic changes typical for endometrioid endometrial cancer are present, including: micro satellite instability; PAX2 inactivation; mutation of PTEN, KRAS and CTNNB1 (β-catenin) 25–33 % [ 5 ] 59 % [ 3 ] RR: 14–45 This reduction to 2 categories was not only due to the need to do away with the confusing multitude of terms currently in use. Rather, it reflects a new understanding of molecular genetic changes. Hyperplasias without atypia exhibit no relevant genetic changes. They are benign changes and will regress again after the endocrine milieu (physiological gestagen levels) has normalized. In a few cases (1–3 %), progression to invasive disease may occur if the endocrine disorder (long-term estrogen dominance or relative or absolute gestagen deficiency) persists over the long term. Atypical endometrial hyperplasias exhibit many of the mutations typical for invasive endometrioid endometrial cancer [ 7 ]. In up to 60 % of cases, patients have coexisting invasive cancer or are at extremely high risk of developing invasive cancer ([ Table 1 ]). The implications for treatment are obvious: hyperplasias without atypia sh
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Munro, M. G., Critchley, H. O. D., Fraser, I. S., & the FIGO Menstrual Disorders Committee (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12666 · Cited by 1,026
New concepts for an old problem: the diagnosis of endometrial hyperplasia
Sanderson, P. A., Critchley, H. O. D., Williams, A. R. W., Arends, M. J., & Saunders, P. T. K. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw042 · Cited by 323
The exciting potential for ChatGPT in obstetrics and gynecology
Grünebaum, A., Chervenak, J., Pollet, S. L., Katz, A., & Chervenak, F. A. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.03.009 · Cited by 234
Metadata
- Authors
- Emons, G., Beckmann, M., Schmidt, D., Mallmann, P., & for the Uterus commission of the Gynecological Oncology Working Group (AGO)
- Venue
- Geburtshilfe und Frauenheilkunde
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-03-16
- Volume
- 75
- Issue
- 02
- Pages
- 135-136
- ISSN
- 0016-5751 (ISSN-L)
- 1438-8804
- OpenAlex
- W2327800659
- Cited by
- 192
- References
- 0
- FWCI
- 9.08
- Type
- journal article
- Language
- de
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New WHO Classification of Endometrial Hyperplasias. https://app.cochat.ai/papers/10.1055/s-0034-1396256
- The paper
- Emons, G., Beckmann, M., Schmidt, D., Mallmann, P., & for the Uterus commission of the Gynecological Oncology Working Group (AGO). (2015). New WHO Classification of Endometrial Hyperplasias. Geburtshilfe und Frauenheilkunde. https://doi.org/10.1055/s-0034-1396256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.